Background: Ovarian cancer (OC) is the most prevalent gynecological malignancy in women, often diagnosed at an advanced stage due to the absence of specific clinical biomarkers. Notch signaling, particularly Notch3, is frequently activated in OC and contributes to its oncogenic role. Despite its known association with poor clinical outcomes, the biomarker potential of Notch3 remains inadequately explored. Methods: We investigated the biomarker potential of Notch3 in OC using multiple databases, including ONCOMINE, GEPIA, Human Protein Atlas, UALCAN, Kaplan–Meier Plotter, and LinkedOmics. We analyzed Notch3 expression levels, survival correlations, and clinicopathological parameters. Results: Notch3 expression was significantly upregulated in OC, as well as other cancers. Correlation analysis demonstrated that high Notch3 mRNA levels were associated with poor overall survival (OS) (p < 0.05) and relapse-free survival (p < 0.05) in OC patients. Human Protein Atlas data showed elevated Notch3 protein levels in OC tissues compared to healthy controls. Clinicopathological analysis indicated significant associations between Notch3 expression and patient age (p < 0.5), TP53 mutation status (p < 0.5), and cancer stage (p < 0.1). Additionally, genes such as WIZ, TET1, and CHD4 were found to be co-expressed with Notch3 in OC. Notch3 expression also correlated with immune cell infiltration in OC. Conclusions: Our bioinformatics analysis highlights Notch3 as a potential biomarker for poor prognosis in OC. However, further in vitro and in vivo studies, along with validation using larger tissue samples, are necessary to confirm its biomarker utility.

Cancer remains a major public health challenge across BRICS member countries. Together, these countries represent more than 40% of the global population and account for approximately 9.0 million new cancer cases and 4.66 million cancer deaths. This review aims to summarize cancer epidemiology across the 11 BRICS member countries, with emphasis on breast and ovarian cancers, describe India’s cancer-control and digital-health architecture, and assess the evidence and translational potential of iOncology.ai. Cancer patterns and access to screening, early diagnosis, and specialist oncology care vary across member countries. Breast cancer is among the leading malignancies affecting women and is the leading female cancer in most BRICS countries. Ovarian cancer is less common but is frequently diagnosed at advanced stages and is associated with poor outcomes. In India, cancer-control activities are delivered through the National Health Mission, the National Programme for Prevention and Control of Non-Communicable Diseases, and complementary surveillance, population-based screening, tertiary-care, and financial-protection mechanisms. The Viksit Bharat 2047 vision and Digital India programme provide a policy context for digital health development, including the Ayushman Bharat Digital Mission. Within this ecosystem, iOncology.ai is an national artificial-intelligence platform undergoing pilot-stage clinical validation and implementation evaluation. The review also identifies priorities for collaborative digital oncology in the context of India’s BRICS Chairship in 2026.